Bayer Builds On Oncology Pipeline With Nycomed’s Divested Kinase Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition of two candidates and back-up compounds complements ongoing Nexavar efforts, Bayer says.
You may also be interested in...
Bayer Beefs Up Biologics Pipeline With Direvo Biotech Buy
Separate spin-out transaction establishes Direvo’s industrial biotech business as an independent entity.
Bayer Beefs Up Biologics Pipeline With Direvo Biotech Buy
Separate spin-out transaction establishes Direvo’s industrial biotech business as an independent entity.
Maxygen Gets $90 Million Cash Infusion From Bayer For Hemophilia Program
Deal will build on Bayer’s hemophilia experience with Kogenate, and provide cash for Maxygen to explore autoimmune programs.